WEBULL

AstraZeneca Stock And 2 Value Picks Trading Below Cash Flow Estimates

Simply Wall St · 1d ago

With bond yields holding near multi year highs, inflation pressures staying sticky in several regions and energy related costs adding extra uncertainty, many investors are rethinking how they value future cash flows. The Undervalued Stocks Based On Cash Flows screener focuses on companies where the SWS DCF valuation suggests the market price is below a reasonable estimate of fair value. This can appeal to value oriented investors who care about what a business can generate in cash over time, not just short term headlines. In this article, you will see 3 of the strongest looking stocks from this screener.

AstraZeneca (LSE:AZN)

Overview: AstraZeneca is a global biopharmaceutical company based in Cambridge that discovers, develops, manufactures, and sells prescription medicines across oncology, cardiovascular, renal and metabolism, respiratory and immunology, vaccines and immune therapies, and rare diseases, serving doctors and patients in the UK, the Americas, Europe, Asia, Africa, and Australasia.

Operations: AstraZeneca generates its revenue primarily from pharmaceuticals, with about US$60.4b coming from this segment.

Market Cap: £193.8b

For investors focused on undervalued future cash flows, AstraZeneca may attract attention because its late stage pipeline and presence in emerging markets sit alongside a Simply Wall St DCF that suggests the current share price is below estimated future cash flow value. Earnings growth has been robust, margins have improved, and returns on equity are high, yet the stock is still priced below some analyst fair value estimates, even after mixed news such as the Wainua trial setback. At the same time, reliance on blockbuster drugs, high R&D spend, elevated debt and increased price pressure from regulators introduce risks, which is why a closer look at the underlying cash flow assumptions can be important here.

AstraZeneca’s high margins and strong returns on equity are being priced like a question mark rather than an advantage, which makes the DCF valuation analysis for AstraZeneca a useful way to see whether blockbuster risk is masking something bigger

AZN Discounted Cash Flow as at Jul 2026
AZN Discounted Cash Flow as at Jul 2026

Kistos Holdings (AIM:KIST)

Overview: Kistos Holdings is a London based energy company focused on discovering, developing, and producing natural gas and other hydrocarbons across the UK, Norway, and the Netherlands, as well as running supporting midstream activities like oil processing, offloading, and gas storage.

Operations: Kistos Holdings generates about US$212.94m in revenue from oil and gas exploration and production, with sales split across Norway, the Netherlands, and the UK.

Market Cap: £224.4m

Kistos Holdings may appeal to investors who are interested in undervalued cash flow stories, as analysts expect earnings to grow faster than revenue, with forecasts pointing to around 27.79% annual earnings growth and high projected returns on equity within three years, even though the company is still loss making today. Recent results show revenue of US$212.94m and a much smaller net loss than the prior year, supported by stronger production in early 2026. At the same time, the stock is indicated as trading well below some fair value estimates. Set against that, there are ongoing losses, a funding structure that leans heavily on external borrowing, and recent insider selling, which means the gap between price and potential cash generation deserves careful scrutiny.

Kistos Holdings looks like an earnings story that has not fully connected with its share price, and the analyst forecasts for Kistos Holdings reveal how that gap could close while flagging one crucial pressure point investors often miss

AIM:KIST Earnings & Revenue Growth as at Jul 2026
AIM:KIST Earnings & Revenue Growth as at Jul 2026

Foresight Group Holdings (LSE:FSG)

Overview: Foresight Group Holdings is a London based investment manager that runs infrastructure, private equity, venture capital and listed funds, giving institutions and retail investors access to assets such as renewable energy, social and digital infrastructure, and smaller private companies. It typically supplies growth capital and buyout funding, often taking majority stakes and providing both equity and credit across a range of sectors and stages.

Operations: Foresight Group Holdings generates about £114.8m of revenue from Real Assets and £50.1m from Private Equity, with the United Kingdom contributing £126.4m and Australia £25.7m of its geographically reported revenue.

Market Cap: £539.6m

Foresight Group Holdings stands out because investors are paying a relatively low P/E multiple for a business that combines reported profitability, with a 27.7% net margin and 47.8% ROE, and fee based exposure to long term themes such as energy transition and infrastructure. The company is increasing earnings and revenue while using buybacks to gradually reduce the share count. This can help support earnings per share as assets under management change in size. At the same time, reliance on performance fees, concentrated exposure to UK and European policy decisions and rising administrative costs mean earnings may fluctuate over time. The key consideration is how these strengths and risks compare when you look at the cash flow based fair value estimates and analyst expectations side by side.

Foresight Group Holdings has a P/E that seems out of sync with its 27.7% net margin and 47.8% ROE, so the analysis report for Foresight Group Holdings could be the missing piece that explains whether performance fees are a quiet swing factor.

FSG Discounted Cash Flow as at Jul 2026
FSG Discounted Cash Flow as at Jul 2026

The 3 stocks here are just a starting point. The full Undervalued Stocks Based On Cash Flows screener surfaces 41 more companies where the Simply Wall St DCF suggests the market price and cash flow story may not fully line up, all grouped inside the Undervalued Stocks Based On Cash Flows screener. Use Simply Wall St to identify and analyze the specific catalysts, cash flow profiles, and valuation narratives that matter most to you so you can focus on your highest conviction ideas.

Take Control of Your Investment Journey

If AstraZeneca or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Alternatives Before The Crowd Moves?

Fresh stocks can start breaking out while everyone watches yesterday's winners. Consider these under the radar ideas before momentum changes, information becomes stale, and potential entry ranges shift.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.